The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Sep. 21, 2010
Filed:
Aug. 22, 2008
Jorge Berlanga Acosta, Ciudad de la Habana, CU;
Jose I. Fernandez Montequin, Ciudad de la Habana, CU;
Calixto Valdes Perez, Ciudad de la Habana, CU;
Neobalis Franco Perez, Ciudad de la Habana, CU;
Ingrid Rojas Constantin, Ciudad de la Habana, CU;
Hector Santana Milian, Ciudad de la Habana, CU;
Larissa Chacon Corvea, Ciudad de la Habana, CU;
Gerardo E. Guillen Nieto, Ciudad de la Habana, CU;
Luis Herrera Martinez, Ciudad de la Habana, CU;
Leonardo Canan-haden Frias, Ciudad de la Habana, CU;
Haydee Geronimo Perez, Ciudad de la Habana, CU;
Jorge Sotolongo Pena, Ciudad de la Habana, CU;
Jorge Berlanga Acosta, Ciudad de la Habana, CU;
Jose I. Fernandez Montequin, Ciudad de la Habana, CU;
Calixto Valdes Perez, Ciudad de la Habana, CU;
Neobalis Franco Perez, Ciudad de la Habana, CU;
Ingrid Rojas Constantin, Ciudad de la Habana, CU;
Hector Santana Milian, Ciudad de la Habana, CU;
Larissa Chacon Corvea, Ciudad de la Habana, CU;
Gerardo E. Guillen Nieto, Ciudad de la Habana, CU;
Luis Herrera Martinez, Ciudad de la Habana, CU;
Leonardo Canan-Haden Frias, Ciudad de la Habana, CU;
Haydee Geronimo Perez, Ciudad de la Habana, CU;
Jorge Sotolongo Pena, Ciudad de la Habana, CU;
Centro de Ingenieria Genetica y Biotecnologia, Ciudad de la Habana, CU;
Abstract
The invention relates to the use of Epidermal Growth Factor (EGF) in a preferably-injectable pharmaceutical composition which is administered by means of infiltration into and around chronic cutaneous ischaemic lesions in order to prevent diabetic foot amputation. Said composition can be administered to recently-created surgical surfaces damaged by the effect of acute reperfusion with oxygenated blood following prolonged ischaemia, thereby preventing further surgical procedures and favoring the preservation of the extremity. The aforementioned composition can be used to improve (i) the cell microenvironment, thereby increasing the reparative and defensive capacity and viability of the is tissues and (ii) the cicatrization of cutaneous ischaemic lesions, thereby stimulating cell proliferation. The invention is suitable for use in human, veterinary and experimental medicine, specifically in vascular angiology and surgery, dermatology, burn treatment and reconstructive surgery and geriatric medicine. Said composition can be used for recalcitrant ulcers which are associated with lesions in the macro and/or microvasculature, patients with inadequate lymphatic and/or venous return and ulcers or other lesions which are difficult to cicatrize and/or heal.